Research and Markets: Ohr Pharmaceuticals's Squalamine Macular Edema and Macular Degeneration Drug Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/xrwfbj/squalamine) has announced the addition of the "Squalamine (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering.

Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Squalamine (Squalamine lactate) is a first-in-class drug being developed by Ohr Pharmaceuticals as a novel eye drop solution treatment for wAMD. This small-molecule drug has a novel intracellular mechanism of action and can potently inhibit multiple protein growth factors involved in angiogenesis, including VEGF, PDGF, and bFGF.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Squalamine including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Squalamine for the top country from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain and UK

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Macular Degeneration Overview

3.2 Macular Edema Overview

4 Disease Management

5 Competitive Assessment

6 Unmet Need and Opportunity

6.1 Overview

6.2 Treatment for Dry AMD

6.3 Longer-Acting Anti-VEGF Drug Therapy

6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD

6.5 Less Invasive Drug Formulations

6.6 Awareness and Earlier Patient Diagnosis

6.7 Home Monitoring of AMD Progression

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

8 Squalamine

9 Appendix

For more information visit http://www.researchandmarkets.com/research/xrwfbj/squalamine

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals